Telix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase – Still a Buy?

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) saw unusually-high trading volume on Friday . 119,252 shares traded hands during trading, a decline of 40% from the previous session’s volume of 197,259 shares.The stock last traded at $11.3040 and had previously closed at $11.90.

Analyst Ratings Changes

Several brokerages have recently commented on TLX. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a research note on Wednesday, September 2nd. Royal Bank Of Canada cut shares of Telix Pharmaceuticals from an “outperform” rating to a “sector perform” rating in a research note on Friday, July 17th. Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. Weiss Ratings raised shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, August 21st. Finally, Wedbush reiterated an “outperform” rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $20.40.

Telix Pharmaceuticals Price Performance

The stock’s fifty day simple moving average is $11.24 and its 200 day simple moving average is $10.13. The company has a current ratio of 2.01, a quick ratio of 1.85 and a debt-to-equity ratio of 1.16.

Institutional Trading of Telix Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in TLX. Rhumbline Advisers lifted its holdings in shares of Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after buying an additional 1,392 shares during the period. XTX Topco Ltd bought a new position in shares of Telix Pharmaceuticals during the 4th quarter worth approximately $89,000. Bank of America Corp DE lifted its position in Telix Pharmaceuticals by 523.8% during the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after acquiring an additional 8,423 shares during the last quarter. OLD Mission Capital LLC purchased a new stake in Telix Pharmaceuticals during the fourth quarter valued at approximately $111,000. Finally, XY Capital Ltd acquired a new stake in Telix Pharmaceuticals in the first quarter valued at approximately $120,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.